These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18329117)

  • 21. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation of efficacy and clinical impact of positron emission tomography with 18F fluoro-deoxyglucose (FDG) in patients with suspicion of recurrent laryngeal carcinoma].
    Alvarez Pérez RM; Borrego Dorado I; Vázquez Albertino R; Ruiz Franco-Baux J; Ceballo Pedraja JM; Esteban Ortega F
    Acta Otorrinolaringol Esp; 2006 Mar; 57(3):134-9. PubMed ID: 16615566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Value of positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) in early detection of residual tumor in oro-pharyngeal-laryngeal carcinoma].
    Haenggeli CA; Dulguerov P; Slosman D; Becker M; Bang P; Allal A; Guyot JP; Lehmann W
    Schweiz Med Wochenschr Suppl; 2000; 116():8S-11S. PubMed ID: 10780061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnosis with (18)F-FDG PET scan after larynx preservation by primary radiochemotherapy].
    Dietz A; Rudat V; Harms W; Jungehülsing M; Dollner R; Henze M
    HNO; 2004 Jan; 52(1):38-44. PubMed ID: 14740113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
    Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
    J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.
    Kahn D; Follett KA; Bushnell DL; Nathan MA; Piper JG; Madsen M; Kirchner PT
    AJR Am J Roentgenol; 1994 Dec; 163(6):1459-65. PubMed ID: 7992747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
    Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H
    Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient.
    Lonneux M; Lawson G; Ide C; Bausart R; Remacle M; Pauwels S
    Laryngoscope; 2000 Sep; 110(9):1493-7. PubMed ID: 10983949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study.
    Langenhoff BS; Oyen WJ; Jager GJ; Strijk SP; Wobbes T; Corstens FH; Ruers TJ
    J Clin Oncol; 2002 Nov; 20(22):4453-8. PubMed ID: 12431968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
    Majhail NS; Urbain JL; Albani JM; Kanvinde MH; Rice TW; Novick AC; Mekhail TM; Olencki TE; Elson P; Bukowski RM
    J Clin Oncol; 2003 Nov; 21(21):3995-4000. PubMed ID: 14581422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report.
    Yao M; Graham MM; Smith RB; Dornfeld KJ; Skwarchuk M; Hoffman HT; Funk GF; Graham SM; Menda Y; Buatti JM
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1410-8. PubMed ID: 15590172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
    De Potter T; Flamen P; Van Cutsem E; Penninckx F; Filez L; Bormans G; Maes A; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer.
    Cho SM; Ha HK; Byun JY; Lee JM; Kim CJ; Nam-Koong SE; Lee JM
    AJR Am J Roentgenol; 2002 Aug; 179(2):391-5. PubMed ID: 12130439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients.
    Moore HG; Akhurst T; Larson SM; Minsky BD; Mazumdar M; Guillem JG
    J Am Coll Surg; 2003 Jul; 197(1):22-8. PubMed ID: 12831920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma.
    Johnson GR; Zhuang H; Khan J; Chiang SB; Alavi A
    Clin Nucl Med; 2003 Oct; 28(10):815-20. PubMed ID: 14508272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors.
    Scanga DR; Martin WH; Delbeke D
    Clin Nucl Med; 2004 Feb; 29(2):86-90. PubMed ID: 14734903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women.
    Unger JB; Ivy JJ; Connor P; Charrier A; Ramaswamy MR; Ampil FL; Monsour RP
    Gynecol Oncol; 2004 Jul; 94(1):212-6. PubMed ID: 15262145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
    Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
    Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Thrall MM; DeLoia JA; Gallion H; Avril N
    Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.